Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 178
- Registration Number
- NCT00612040
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Umeå, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath